Oncology drug efficacy is evaluated in mouse models by continuously monitoring tumor volumes, which can be mathematically described by growth kinetic models. While past studies have investigated various growth models, their reliance on small datasets raises concerns about whether their findings are truly representative of tumor growth in diverse mouse models under different vehicle or drug treatments. Here, we systematically evaluated six parametric models (exponential, exponential quadratic, monomolecular, logistic, Gompertz, and von Bertalanffy) and the semi-parametric generalized additive model (GAM) on fitting tumor volume data from over 30,000 mice in 930 experiments conducted in patient-derived xenografts, cell line-derived xenografts, and syngeneic models. We found that the exponential quadratic model is the best parametric model and can adequately model 87% studies, higher than other models including von Bertalanffy (82%) and Gompertz (80%) models, the latter is often considered the standard growth model. On the mouse group level, 7.5% of growth data could not be fit by any parametric model and were fitted by GAM. We show that eGaIT, a GAM derived efficacy metric, is equivalent to eGR, a metric we previously proposed and conveniently calculated by simple algebra. Using five studies on Paclitaxel, anti-PD-1 antibody, Cetuximab, Irinotecan, and Sorafenib, we show that exponential and exponential quadratic models achieve similar performance in uncovering drug mechanism and biomarkers. We also compared eGR-based association analysis and exponential modeling approach in biomarker discovery and found they complement each other. Modeling methods herein are implemented in an open-source R package freely available at https://github.com/hjzhou988/TuGroMix.
Read full abstract